Methylation of p16 and E-cadherin in ameloblastoma

Chan-Woong Park¹, Hye-Kyoung Yoon², Sang-Jun Park¹
Departments of ¹Oral and Maxillofacial Surgery, ²Pathology,
Pusan Paik Hospital, College of Medicine, Inje University, Busan, Korea


Introduction: Ameloblastic carcinoma is a rare malignant lesion, and may arise from either carcinoma ex-ameloblastoma or de novo carcinoma. Aberrant promoter hypermethylation of the tumor-associated genes leading to their inactivation is a common event in many cancer types. The p16/CDKN2/INK4A gene and p16 5 protein are involved directly in regulating the cell cycles. Cadherins are cell adhesion molecules that modulate the epithelial phenotype and regulate tumor invasion. The aim of this study was to evaluate the roles of p16 and E-cadherin methylation and loss of p16 and E-cadherin expression in the malignant transformation of an ameloblastoma.

Materials and Methods: Eight cases of ameloblastoma, including 4 benign ameloblastomas without recurrence, 2 benign ameloblastomas with recurrence and 2 carcinoma ex-ameloblastomas, were examined. The promoter hypermethylation profile of the p16 and E-cadherin genes was studied using methylation-specific polymerase chain reaction (MSP) and immunohistochemical staining for p16 and E-cadherin expression.

Results:
1) Aberrant CpG island methylation of the p16 gene was detected in 3 of the 4 benign ameloblastomas without recurrence and 1 of the 2 benign ameloblastomas with recurrence.
2) Aberrant CpG island methylation of the E-cadherin gene was found in 1 of the 4 benign ameloblastomas without recurrence.
3) A loss of p16 expression was noted in 1 of 4 benign ameloblastomas without recurrence and 1 of 2 carcinoma ex-ameloblastomas.
4) A loss of E-cadherin expression was noted in 2 of the 4 benign ameloblastomas without recurrence, 1 of the 2 benign ameloblastomas with recurrence and 2 of the 2 carcinoma ex-ameloblastomas.
5) A loss of p16 expression was observed in 1 of the 4 cases showing aberrant methylation of the p16 gene.
6) A loss of E-cadherin expression was observed in 3 benign ameloblastoma cases showing aberrant methylation of the E-cadherin gene.

Conclusion: These results suggest that loss of E-cadherin expression related to the other genetic pathway (not methylation) might be an adjuvant indicator predicting the malignant transformation of an ameloblastoma. However, the number of samples in this study was too small and the relationship between the treatment methods and clinical course were not defined. Therefore, further study will be needed.

Key words: p16 genes, Cadherins, Methylation, Ameloblastoma

[paper submitted 2010. 7. 16 / revised 2010. 11. 19 / accepted 2010. 12. 10]
Hypermethylation of tumor suppressor genes p15 and p16 can be detected in several types of malignant tumors including oral squamous cell carcinoma (SCC). Abiko et al. reported that hypermethylation of p16 may have been involved in the malignant transformation of the ameloblastoma in the present case. Hypermethylation of CpG islands of the p16 gene was detected in the malignant parts of the tumor.

Loss of E-cadherin will result in increasing invasiveness and metastatic potential of neoplastic cells. In oral squamous cell carcinoma, hypermethylation of the E-cadherin promoter has recently been demonstrated. Considerable differences have been observed in the incidence alteration by mutations or aberrant methylation of the CpG islands of different regulator genes. The incidence of lost expression due to methylation in E-cadherin is more occasional than for p16.

This study was conducted to explore the hypermethylation and immunohistochemical studies for p16 and E-cadherin genes in the histologically benign ameloblastoma (non-recurred group versus recurred group) and ameloblastic carcinoma (carcinoma ex-ameloblastoma).

### Materials and Methods

#### 1. Patient and samples

Tissue samples from 8 cases, including 4 benign ameloblastomas without recurrence, 2 benign ameloblastomas with recurrence and 2 carcinoma ex-ameloblastomas, diagnosed as ameloblastoma during a period from 1991 to 2004 were selected from the files of department of oral and maxillofacial surgery, Pusan Paik Hospital. They were obtained from the patients ranged in age from 13 to 70 years old, and 6 were male and 2 female. The tumors were located in the mandible in 7 cases, and 1 case with multiple recurrences was located in the maxilla.

#### 2. Histopathological Review

Based on the hematoxylin and eosin (H&E) findings, the ameloblastoma cases were re-classified into benign ameloblastoma without or with recurrence, carcinoma ex-ameloblastoma and malignant ameloblastoma de novo.

#### 3. Methylation study for p16 and E-cadherin genes

1) Genomic DNA extraction

Ten or more sections were obtained from each paraffin blocks as samples. Paraffin-embedded tissue thin sections (5 μm thick, 10 sections) were obtained as sample. From the slides, the tumor tissues, corresponding to the marking sites on H&E slide, were taken. Genomic DNA was isolated using ZYMO Pinpoint Slide DNA Isolation System (Cat. No. D3001, Zymo research, Orange, CA, USA) after deparaffinized with xylene. DNA was recognized using 1% Agarose gel electrophoresis.

2) Sodium bisulfite modification

One μg of each DNA sample was undergone bisulfite modification prior to polymerase chain reaction (PCR) amplification using the ZYMO EZ DNA Methylation Kit (Cat. No. D5002, Zymo research, Orange, CA, USA). This experimental procedure was done according to the manufacturer’s instructions. Briefly, A mixture of 90 μL DNA solution and 10 μL M-dilution buffer was incubated at 37°C for 15 minutes. After loading a mixture into Zymo-Spin I Column and centrifuging (11,000 rpm) for 1 minute at 25°C, the waste products in the collection tube were discarded. After this step, M-Wash buffer 200 μL M-desulphonation buffer was loaded and incubated for 15 minutes at room temperature, and then centrifuged for 1 minute at 25°C, and then 200 μL M-wash buffer was loaded and centrifuged for 1 minute at 25°C.

3) Methylation specific PCR and Electrophoresis

Amplitaq Gold 0.5 unit for p16 and E-cadherin (Roche, Madison, WI, USA) was used to detect methylated sequence in mixed cell populations (methylated and unmethylated) for analysing DNA hypermethylation of p16 and E-cadherin genes. PCR reaction mix consisted of 1 × PCR buffer, each 2.5 mM dNTP, each primer set, 1 unit of HotStarTaq DNA polymerase (Qiagen, cat. No.203203, Germantown, MD, USA) and modified genomic DNA. The primers used for the detection of

<p>| Table 1. Oligonucleotide sequence used in methylation and unmethylation of 5'-UTR Promotor Region CpG island |
|-----------------|-----------------|-----------------|-----------------|-----------------|</p>
<table>
<thead>
<tr>
<th><strong>Gene</strong></th>
<th><strong>Ori</strong></th>
<th><strong>Oligonucleotide sequence (5' to 3')</strong></th>
<th><strong>PCR products (bp)</strong></th>
<th><strong>Cancer cell-line</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>E-cadherin</td>
<td>MF</td>
<td>TGATGTTAAGCTATTTTTTATTGCGTC</td>
<td>112 bp</td>
<td>MIA-PACA2</td>
</tr>
<tr>
<td>MR</td>
<td>CGAACATCGATCGAATCGAACCG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p16</td>
<td>MF</td>
<td>TTATTAGAGGCTGGCGCTGACG</td>
<td>150 bp</td>
<td>T-24</td>
</tr>
<tr>
<td>MR</td>
<td>GACCGCGAACCGCGACCGTAA</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
methylation and unmethylation were described in Table 1, respectively. The reactions were hotstarted at 95°C for 15 minutes, and were carried out for 40 cycles (45 seconds at 95°C, variable annealing time and temperatures according to the primer, and 60 seconds at 72°C) and a final 10 minutes extension at 72°C in a thermal cycler (MJ Research, Waltham, MA, USA). PCR products were separated by electrophoresis on a 2% agarose gel, then visualized under ultraviolet (UV) illumination using an ethidium bromide stain.

4) Sequencing
The PCR products suggested to harbor mutation were cloned, and recombinant double-stranded plasmid DNA was sequenced by automatic sequencer using an AutoRead 100 sequencing kit (Pharmacia, Stockholm, Sweden).

4. Immunohistochemical stain for p16 and E-cadherin
Formalin-fixation and paraffin-embedding tissues were sectioned at 4-6 μm and deparaffinized in xylene and rehydrated in ethanol. The slides were incubated with pretreatment for 30 minutes at 99°C. The sections were incubated with 3% peroxidase blocking solution for 10 minutes at room temperature for endogenous peroxidase and incubated with primary antibody at appropriate dilution in primary antibody dilution buffer for 1 hour at room temperature. Commercially available primary antibodies directed against p16 (1:2,000, Abcam, Cambridge, UK) and E-cadherin (1:25, Abcam, Cambridge, UK) were applied. Biotinylated secondary antibody and streptavidin-HRP was carried out using the Envision system (Dako, Glostrup, Denmark). Chromogen was incubated in diaminobenzidine (DAB) (Dako, Glostrup, Denmark) for 10 minutes at room temperature. The slides was developed with Mayer’s hematoxylin for counter staining, dehydrated through alcohol, and cleared in xylene prior to cover slipping for microscopic examination.

Immunohistochemical stains for p16 and E-cadherin were interpreted as partial loss or total loss of expressions according to the extent of loss of expressions. If more than half of tumor tissue were negative, it was defined as total loss, and if the less than half of tumor tissue were negative, it was categorized as partial loss.

Ⅲ. Results

1. Methylation study for p16 and E-cadherin
Aberrant CpG island methylation of p16 was detected in 4 of 8 cases. (Figs. 1, 2) Four cases showing p16 methylation are benign ameloblastoma, and 3 of them showed no recurrence and 1 case was recurred. None of 2 cases of carcinoma ex-amebloblastoma showed aberrant CpG island methylation of p16. Aberrant CpG island methylation of E-cadherin was found in 1 of 8 cases. (Figs. 3, 4) One case showing methylation of E-cadherin was benign ameloblastoma with no recurrence. (Table. 2)

2. Immunohistochemical findings for p16 and E-cadherin
Total or partial loss of p16 expression were noted 4 of 8 cases. (Fig. 5) Two cases showing total loss of p16 expression were one benign ameloblastoma and one carcinoma arising in benign ameloblastoma. Two cases exhibiting partial loss of p16 expression were benign ameloblastoma cases, and 1 of them was recurred case. (Fig. 6, Table. 2)

Loss of E-cadherin expression was noted in 5 of 8 cases. Total loss of E-cadherin expression was noted in 2 cases: one was recurred ameloblastoma and the other carcinoma ex-amebloblastoma. Partial loss of E-cadherin expression was not-
ed in 2 of 4 benign ameloblastoma cases and 1 of carcinoma ex-ameloblastoma.

3. Comparison of methylation and immunohistochemical studies

Among 4 benign ameloblastoma cases, methylation of p16 gene was noted in 3 cases. One of 3 cases with aberrant p16 gene methylation showed partial loss of p16 expression. One benign ameloblastoma case showing aberrant E-cadherin methylation revealed partial loss of E-cadherin expression.

In 2 cases of benign ameloblastoma with recurrence, 1 case showed aberrant p16 gene methylation, but loss of p16 expression was not accompanied. Another 1 case of benign ameloblastoma with recurrence showed loss of E-cadherin expression.

Fig. 3. Bisulfite genomic sequencing result of 5’CpG island of the E-cadherin gene.

Fig. 4. SSCP analysis of the E-cadherin gene in ameloblastoma. Lane 2 shows corresponding band to C+ line. (BL: blank, C+: positive cell line, N/C: negative control, SSCP: single strand conformational polymorphism)

Fig. 5. Loss of p16 expression in benign ameloblastoma without recurrence (upper) and with recurrence (middle), and carcinoma ex-ameloblastoma (lower).

Fig. 6. Loss of E-cadherin expression in benign ameloblastoma without recurrence (1st lane) and with recurrence (2nd lane), and in carcinoma ex-ameloblastoma (3rd and 4th lane).
expression, even though aberrant E-cadherin gene methylation was not noted.

In 2 cases showing carcinoma arising in ameloblastoma, 1 case revealed loss of p16 expression but aberrant methylation of p16 gene was not associated in this case. Two cases showing carcinoma arising in ameloblastoma exhibited loss of E-cadherin expression even though no aberrant methylation of E-cadherin. (Table 3)

Table 2. Profiles of methylation specific PCR and immunohistochemical findings for p16 and E-cadherin in the ameloblastomas

<table>
<thead>
<tr>
<th>Case</th>
<th>Methylation specific PCR</th>
<th>Immunohistochemistry</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>p16</td>
<td>E-cadherin</td>
</tr>
<tr>
<td>Benign A. without recurrence</td>
<td>1+</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>2-</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>3+</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>4+</td>
<td>-</td>
</tr>
<tr>
<td>Benign A. with recurrence</td>
<td>5+</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>6-</td>
<td>-</td>
</tr>
<tr>
<td>Carcinoma ex-A.</td>
<td>7-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>8-</td>
<td>-</td>
</tr>
</tbody>
</table>

(PCR: polymerase chain reaction, A: ameloblastoma)

Table 3. Comparison of methylation specific PCR and immunohistochemical findings for p16 and E-cadherin in the ameloblastomas

<table>
<thead>
<tr>
<th>n</th>
<th>p16</th>
<th>E-cadherin</th>
<th>IHC</th>
<th>Total loss</th>
<th>IHC</th>
<th>Total loss</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benign A. without recurrence</td>
<td>4</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Benign A. with recurrence</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Carcinoma ex-A.</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td>8</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>3</td>
</tr>
</tbody>
</table>

(PCR: polymerase chain reaction, MSP: methylation specific PCR, IHC: immunohistochemical staining, A: ameloblastoma)

In V. Discussion

Ameloblastoma is a locally infiltrative, benign, odontogenic neoplasm typically arising in the posterior regions of the jaws. Approximately 80% of ameloblastomas were reported to occur in the mandible, and 20% in the maxilla. A rare, malignant variant of ameloblastoma was first described in the medical literature in 1950. The World Health Organization separated this variant into its current subtypes, ie, malignant ameloblastoma and ameloblastic carcinoma, in 1972. This classification was further revised by Slootweg and Muller in 1984. The World Health Organization described malignant ameloblastoma as a tumor showing the histopathologic features of classic ameloblastoma with metastatic deposits, and defined ameloblastic carcinoma as an epithelial proliferation with histopathologic features of malignancy, either associated with an ameloblastoma (carcinoma ex-ameloblastoma) or representing a de novo carcinoma that resembles ameloblastoma histopathologically.

Epigenetic alterations such as hypermethylation of CpG islands of tumor suppressor gene may lead to suppression of transcription, which induces malignant transformation. Hypermethylation of tumor suppressor genes such as p16 and E-cadherin affect DNA repair. DNA methylation could change in response to environmental, physiological and biological signals.

The DNA methylation profile of cancer cells is characterized by global hypomethylation and simultaneous hypermethylation of selected CpG island gene promoters. Recently, the epigenetic phenomenon of DNA promoter methylation has gained increasing recognition as an important mechanism for transcriptional inactivation of cancer related genes. The identification of these methylation alterations and elucidation of the mechanistic events are important, as the methylation status of cancer cells can now be manipulated in vivo with demethylating chemotherapeutics.

The p16 gene encodes a cell cycle protein which inhibits cyclin dependent kinase 4 and 6, and genetic alteration of the
p16 genes, leading to its inactivation, may result in degeneration of cell proliferation and tumorigenesis. The p16 tumor suppressor gene acts as a negative regulator of cellular proliferation, and inactivation of p16, related with homozygous deletions, mutations and hypermethylation, is a frequent event in human oral squamous cell carcinoma. Hypermethylation of tumor suppressor genes p15 and p16 can be detected in several types of malignant tumors including oral squamous cell carcinoma.

According to Zhao et al., the p16 gene was altered and inactivated by methylation or mutation in a significant proportion of maxillofacial SCC. Twenty two cases (34%) were methylated and 7 (11%) displayed point mutations and the total frequency of alteration of the p16 gene was 43% (28/65). Loss of p16 protein expression was noted in 17 (67%) of 27 SCC cases. Among 17 cases with loss of p16 protein expression, 10 cases showed methylation and 3 cases revealed mutations, which may suggest that methylation and mutation of the p16 gene might account for the loss of p16 expression.

The hypermethylation of p16 may cause deregulation of cellular proliferation in ameloblastoma. Abiko et al. reported that hypermethylation of p16 may have been involved in the malignant transformation of the ameloblastoma in the present case. Hypermethylation of CpG islands of the p16 gene was detected in the malignant parts of the tumor. Nodit et al. reported allelic loss of p16 genes in ameloblastic tumors, but no significant difference between ameloblastic carcinomas and benign ameloblastomas, so other genetic or epigenetic mechanism (not allelic loss) might be responsible for malignant behavior in ameloblastic carcinomas.

In present study, aberrant CpG island methylation of p16 was detected in 4 of 8 cases. Three of 4 cases were benign ameloblastoma without recurrence and 1 case was recurred. None of carcinoma ex-ameloblastoma revealed aberrant CpG island methylation of p16. These findings suggest that aberrant methylation of p16 gene might be associated with ameloblastoma but not related to the malignant transformation of ameloblastoma. Loss of p16 protein expression were noted 4 of 8 cases. One of 2 cases showing total loss of p16 protein expression was benign ameloblastoma and the other carcinoma ex ameloblastoma. Partial loss of p16 expression were observed in benign ameloblastoma with or without recurrence. These findings indicated that loss of p16 expression was associated with benign to malignant ameloblastoma, and was not a marker of malignant transformation. Only one of 4 cases showing aberrant methylation of p16 gene showed partial loss of p16 expression. There were no overt relationship between aberrant methylation of p16 gene and loss of p16 protein expression.

According to these results, loss of p16 protein expression in the ameloblastomas might be related to the aberrant methylation and another genetic alterations.

In oral squamous cell carcinoma, hypermethylation of the E-cadherin promoter has recently been demonstrated. Considerable differences have been observed in the incidence alteration by mutations or aberrant methylation of the CpG islands of different regulator genes. The incidence of lost expression due to methylation in E-cadherin is more occasional than for p16. Methylation is one possible step towards DNA damage, and the same evolutionary pressure will favor all processes of silencing same genes in carcinogenesis. Loss of E-cadherin is related to the increased invasiveness and metastatic potential of neoplastic cells, but several alternative routes to the loss of E-cadherin can be expected in the human tumors. Similarly, there must be a high number of genes with relatively low incidence of aberrant silencing by methylation or mutation, reflecting abundant alternative routes in the multistep process of carcinogenesis.

According to Abiko et al., hypermethylation of E-cadherin was not observed in the benign and malignant ameloblastoma. In this study, aberrant CpG island methylation of E-cadherin was found in only one case among 8 cases, and this case was benign ameloblastoma with no recurrence. These results suggest that aberrant methylation of E-cadherin gene seems to be a very rare event in the development of ameloblastoma, and not a suggesting finding of malignant transformation in the ameloblastoma. In contrast to methylation results, loss of E-cadherin expression was noted in 5 cases, and 3 cases showed partial loss of E-cadherin expression, and 2 of them were benign ameloblastoma and another one was carcinoma ex-ameloblastoma, and complete loss of E-cadherin expression, was noted in 2 cases, 1 recurred ameloblastoma and 1 carcinoma ex-ameloblastoma. Based on E-cadherin expression findings, complete loss of E-cadherin expression might be an adjuvant marker of recurrence or malignant transformation in the ameloblastoma.

Aberrant E-cadherin methylation was noted in only one benign ameloblastoma case, accompanying partial loss of E-cadherin expression. Remaining 4 cases showing loss of E-cadherin expression revealed no evidence of aberrant methylation of E-cadherin gene.

Aberrant methylation of E-cadherin gene may be a rare event in the development of ameloblastoma, in contrast, loss of E-cadherin expression is relatively common. These results suggest that loss of E-cadherin expression related to the other genetic pathway, not to methylation, might be a adjuvant indicator to predict the malignant transformation of ameloblastoma.
This study had some limitations. Because ameloblastic carcinoma is very rare entity of the cancer, too small samples were included. And treatment methods were not defined in all sample, the relation between clinical and pathologic results were not included. Further study need to be continued with proper sample size and clinical follow-up.

V. Conclusion

Aberrant methylation of p16 gene or loss of p16 expression might be associated with ameloblastoma but not related to the malignant transformation of ameloblastoma, and loss of p16 expression in the ameloblastomas might be related to the aberrant methylation and another genetic alterations. Aberrant methylation of E-cadherin gene might be a rare event in the development of ameloblastoma, in contrast, loss of E-cadherin expression is relatively common. These results suggest that loss of E-cadherin expression related to the other genetic pathway, not to methylation, might be a adjuvant indicator to predict the malignant transformation of ameloblastoma.

References